1. Whelan J, Vlahos N. The ovarian hyperstimulation syndrome. Fertil Steril 2000; 73:883-896. [
DOI:10.1016/S0015-0282(00)00491-X]
2. Roest J. Severe OHSS: An 'epidemic' caused by doctors. Hum Reprod 1999; 14: 2183. [
DOI:10.1093/humrep/14.9.2183]
3. Bergh PA, Navot D. Ovarian hyperstimulation syndrome: a review of pathophysiology. J Assist Reprod Genet 1992; 9:429- 438. [
DOI:10.1007/BF01204048]
4. Brinsden PR. Diagnosis, Prevention and management of OHSS. Br J Obstet Gynecol 1995; 102:767-772. [
DOI:10.1111/j.1471-0528.1995.tb10840.x]
5. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994; 26:26988-26995.
6. Verheul HM, Hoekman K, Jorna AS, Smit EF, Pinedo HM. Targeting vascular endothelial growth factor blockage: ascites and pleural effusion formation. Oncologist 2000; 5:s45-s50. [
DOI:10.1634/theoncologist.5-suppl_1-45]
7. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 2002; 8:559 -577. [
DOI:10.1093/humupd/8.6.559]
8. Egbase PE, Makhseed M, Al Sharhan M, Grudzinskas JG. Timed unilateral follicular aspiration prior to administration of human chorionic gonadotropin for the prevention of severe ovarian hyperstimulation syndrome in in-vitro fertilization:a prospective randomized study. Hum Reprod 1997; 12:2603-2606. [
DOI:10.1093/humrep/12.12.2603]
9. Aflatoonian A, Dehghani-Firouzabadi R, Kalantar SM, Solimani M, Karymzadeh-Mibodi MA, Taheripanah R, et al. The role of aspiration of half of ovarian follicles prior to administration of hCG or GnRH-a for prevention of severe OHSS in ART programs. Middle East Fertility Society Journal 2000; 5:73-75.
10. Queenan JTJr, Veeck LL, Toner JP, Oehninger S, Muasher SJ. Cryopreservation of all prezygotes in patients at risk of severe hyperstimulation does not eliminate the syndrome, but the chances of pregnancy are excellent with subsequent frozen-thaw transfers. Hum Reprod 1997; 12:1573-1576. [
DOI:10.1093/humrep/12.7.1573]
11. Rabinovici J, Kushnir O, Shalev J, Goldenberg M, Blankstein J. Rescue of menotrophin cycles prone to develop ovarian hyperstimulation. Br J Obstet Gynecol 1987; 94:1098-1102. [
DOI:10.1111/j.1471-0528.1987.tb02297.x]
12. Urman B, Pride SM, Yuen BH. Management of overstimulated gonadotrophin cycles with a controlled drift period. Hum Reprod 1992; 7:213-217. [
DOI:10.1093/oxfordjournals.humrep.a137619]
13. Schenker JG .Prevention and treatment of ovarian hyperstimulation. Hum Reprod 1993; 8:653-659. [
DOI:10.1093/oxfordjournals.humrep.a138115]
14. Ben-Nun I, Shulman A, Ghetler Y, Shilon M, Kaneti H , Beyth Y. The significance of 17 beta-estradiol levels in highly responding women during ovulation induction in IVF treatment: its impact and prognostic value with respect to oocyte maturation and treatment outcome. J Assist Reprod Genet 1993; 10:213-215. [
DOI:10.1007/BF01239223]
15. Alvarez C, Bosch E, Melo MAB, Fernandez-Sanchez M, Munoz EA, Remohi J, et al. The dopamine agonist cabergoline prevents moderate-severe early ovarian hyperstimulation syndrome (OHSS) in high-risk patients. Hum Reprod 2006; 21: i96.
16. Tiitinen A, Husa LM, Tulppala M, Simberg N, Seppala M. The effect of cryopreservation in prevention of ovarian hyperstimulation syndrome. Br J Obstet Gynaecol 1995; 102:326-329. [
DOI:10.1111/j.1471-0528.1995.tb09140.x]
17. Sher G, Salem R, Feinman M, Dodge S, Zouves C, Knutzen V. Eliminating the risk of life-endangering complications following overstimulation with menotropin fertility agents: a report on women undergoing in vitro fertilization and embryo transfer. Obstet Gynecol 1993; 81:1009-1011.
18. Aflatoonian A, Mahani IM, Tabibnejad N. Comparison of coasting with aspiration half of follicles before HCG injection for prevention of OHSS in ART cycles. Hum Reprod 2006; 21: s137.
19. Alvarez C, Gonzalez S, Crespo J, Simón C, Remohı́ J, Pellicer A. Cabergoline (Cb2) administration to prevent ovarian hyperstimulation syndrome (OHSS) in IVF ICSI does not reduce implantation and pregnancy rates. Fertil Steril 2006; 86: s337. [
DOI:10.1016/j.fertnstert.2006.07.916]
20. Gomez R, Gonzalez M, Zimmermann R, Remohi J, Simon C , Pellicer A. Segregation of the antiapermeability and the antiangiogenic effects derived from VEGFR2 blockade by cabergoline. A specific non-toxic approach to treat OHSS. Fertil Steril 2006; 86: s45. [
DOI:10.1016/j.fertnstert.2006.07.124]
21. Tortoriello DV, McGovern PG, Colon JM, Skurnick JH, Lipetz K, Santoro N. "Coasting" does not adversely affect cycle outcome in a subset of highly responsive in vitro fertilization patients. Fertil Steril 1998; 69: 454-460. [
DOI:10.1016/S0015-0282(97)00560-8]
22. Enskog A, Henriksson M, Unander M, Nilsson L, Brännström M. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril 1999; 71: 808-814. [
DOI:10.1016/S0015-0282(99)00090-4]
23. Waldenstrom U, Kahn J, Marsk L, Nilsson S. High pregnancy rates and successful prevention of severe ovarian hyperstimulation syndrome by prolonged coasting of very hyperstimulated patients: a multicentre study. Hum Reprod 1999; 14:294-297. [
DOI:10.1093/humrep/14.2.294]
24. Ulug U, Bahceci M, Erden HF, Shalev E, Ben-Shlomo. The significance of coasting duration during ovarian stimulation for conception in assisted fertilization cycles. Hum Reprod 2002; 17: 310-313. [
DOI:10.1093/humrep/17.2.310]
25. Speroff L, Fritz MA. Induction of ovulation. In: Clinical Gynecologic Endocrinology and Infertility. Los Angeles. Lippincott Williams & Wilkins 2005: 1175-1214.
26. Crosignani PG. Management of hyperprolactiaemic infertility. In: Ovulation induction. Paris. ELSEVIER, 2002: 79-86.